Acurx Pharmaceuticals Inc
Company Profile
Business description
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
Contact
259 Liberty Avenue
Staten IslandNY10305
USAT: +1 917 533-1469
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
4
Stocks News & Analysis
stocks
AI stocks stumble amid growing safety fears
stocks
Chart of the Week: BHP’s valuation hits historic levels
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,920.00 | 9.10 | 0.10% |
| CAC 40 | 8,186.93 | 0.00 | 0.00% |
| DAX 40 | 25,716.71 | 178.96 | 0.70% |
| Dow JONES (US) | 51,778.04 | 316.14 | 0.61% |
| FTSE 100 | 10,816.14 | 127.67 | 1.19% |
| HKSE | 24,774.38 | 170.09 | 0.69% |
| NASDAQ | 26,418.30 | 439.87 | 1.69% |
| Nikkei 225 | 64,662.11 | 525.86 | 0.82% |
| NZX 50 Index | 13,650.60 | 105.99 | -0.77% |
| S&P 500 | 7,637.76 | 85.95 | 1.14% |
| S&P/ASX 200 | 8,731.20 | 1.20 | -0.01% |
| SSE Composite Index | 3,911.05 | 35.45 | 0.91% |